Uy Ear
Stock Analyst at Mizuho
(4.31)
# 408
Out of 5,118 analysts
77
Total ratings
53.19%
Success rate
19.45%
Average return
Main Sectors:
Stocks Rated by Uy Ear
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| NBIX Neurocrine Biosciences | Maintains: Neutral | $146 → $175 | $143.64 | +21.83% | 11 | Dec 12, 2025 | |
| QURE uniQure | Maintains: Outperform | $60 → $33 | $24.56 | +34.36% | 6 | Dec 9, 2025 | |
| EOLS Evolus | Maintains: Outperform | $20 → $19 | $6.66 | +185.29% | 4 | Dec 2, 2025 | |
| ACAD ACADIA Pharmaceuticals | Maintains: Neutral | $24 → $29 | $27.26 | +6.38% | 15 | Dec 2, 2025 | |
| ARQT Arcutis Biotherapeutics | Maintains: Outperform | $32 → $37 | $28.51 | +29.78% | 15 | Nov 28, 2025 | |
| RLMD Relmada Therapeutics | Upgrades: Outperform | $1 → $10 | $4.44 | +125.23% | 2 | Nov 19, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $19 → $26 | $21.83 | +19.13% | 9 | Nov 5, 2025 | |
| ALKS Alkermes | Maintains: Outperform | $40 → $45 | $28.01 | +60.66% | 6 | Oct 27, 2025 | |
| MBX MBX Biosciences | Maintains: Outperform | $38 → $56 | $31.06 | +80.30% | 2 | Sep 24, 2025 | |
| TECX Tectonic Therapeutic | Maintains: Outperform | $51 → $85 | $20.79 | +308.85% | 2 | May 15, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $40 | $6.43 | +522.08% | 1 | May 24, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $40 | $207.56 | -80.73% | 1 | Jun 7, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $10 | $2.28 | +338.60% | 1 | Mar 17, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $5 → $3 | $1.48 | +102.70% | 2 | Mar 1, 2023 |
Neurocrine Biosciences
Dec 12, 2025
Maintains: Neutral
Price Target: $146 → $175
Current: $143.64
Upside: +21.83%
uniQure
Dec 9, 2025
Maintains: Outperform
Price Target: $60 → $33
Current: $24.56
Upside: +34.36%
Evolus
Dec 2, 2025
Maintains: Outperform
Price Target: $20 → $19
Current: $6.66
Upside: +185.29%
ACADIA Pharmaceuticals
Dec 2, 2025
Maintains: Neutral
Price Target: $24 → $29
Current: $27.26
Upside: +6.38%
Arcutis Biotherapeutics
Nov 28, 2025
Maintains: Outperform
Price Target: $32 → $37
Current: $28.51
Upside: +29.78%
Relmada Therapeutics
Nov 19, 2025
Upgrades: Outperform
Price Target: $1 → $10
Current: $4.44
Upside: +125.23%
Sarepta Therapeutics
Nov 5, 2025
Upgrades: Outperform
Price Target: $19 → $26
Current: $21.83
Upside: +19.13%
Alkermes
Oct 27, 2025
Maintains: Outperform
Price Target: $40 → $45
Current: $28.01
Upside: +60.66%
MBX Biosciences
Sep 24, 2025
Maintains: Outperform
Price Target: $38 → $56
Current: $31.06
Upside: +80.30%
Tectonic Therapeutic
May 15, 2025
Maintains: Outperform
Price Target: $51 → $85
Current: $20.79
Upside: +308.85%
May 24, 2024
Initiates: Buy
Price Target: $40
Current: $6.43
Upside: +522.08%
Jun 7, 2023
Maintains: Buy
Price Target: $36 → $40
Current: $207.56
Upside: -80.73%
Mar 17, 2023
Reiterates: Buy
Price Target: $10
Current: $2.28
Upside: +338.60%
Mar 1, 2023
Maintains: Buy
Price Target: $5 → $3
Current: $1.48
Upside: +102.70%